110 related articles for article (PubMed ID: 2483885)
1. Vaccination against HIV and SIV.
Leclerc C
Curr Opin Immunol; 1989-1990 Feb; 2(3):428-32. PubMed ID: 2483885
[No Abstract] [Full Text] [Related]
2. Vaccination against SIV infection and disease.
Gardner MB
AIDS Res Hum Retroviruses; 1990 Jul; 6(7):835-46. PubMed ID: 2167709
[No Abstract] [Full Text] [Related]
3. Progress in vaccine development against SIV and HIV.
Bolognesi DP
J Acquir Immune Defic Syndr (1988); 1990; 3(4):390-4. PubMed ID: 1690288
[No Abstract] [Full Text] [Related]
4. Rationally Designed Vaccines Targeting the V2 Region of HIV-1 gp120 Induce a Focused, Cross-Clade-Reactive, Biologically Functional Antibody Response.
Zolla-Pazner S; Powell R; Yahyaei S; Williams C; Jiang X; Li W; Lu S; Wang S; Upadhyay C; Hioe CE; Totrov M; Kong X
J Virol; 2016 Dec; 90(24):10993-11006. PubMed ID: 27630234
[TBL] [Abstract][Full Text] [Related]
5. Comparative approach to retroviral vaccines.
Burny A
AIDS Res Hum Retroviruses; 1996 Mar; 12(5):389-92. PubMed ID: 8882316
[No Abstract] [Full Text] [Related]
6. Animal models for HIV infection and AIDS: memorandum from a WHO meeting.
Bull World Health Organ; 1988; 66(5):561-74. PubMed ID: 2850118
[TBL] [Abstract][Full Text] [Related]
7. Current approaches to vaccination against human immunodeficiency viruses.
Gluckman JC; Yagello M; Bahraoui E; Girard M
Allergol Immunopathol (Madr); 1991; 19(1):11-3. PubMed ID: 1719790
[No Abstract] [Full Text] [Related]
8. Development of a vaccine for the prevention of AIDS, a critical appraisal.
Karzon DT; Bolognesi DP; Koff WC
Vaccine; 1992; 10(14):1039-52. PubMed ID: 1281948
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of immune responses induced by HIV-1 gp120 in rhesus macaques: effect of vaccination on challenge with pathogenic strains of homologous and heterologous simian human immunodeficiency viruses.
Kumar A; Lifson JD; Silverstein PS; Jia F; Sheffer D; Li Z; Narayan O
Virology; 2000 Aug; 274(1):149-64. PubMed ID: 10936096
[TBL] [Abstract][Full Text] [Related]
10. HIV-1 neutralization: the consequences of viral adaptation to growth on transformed T cells.
Moore JP; Ho DD
AIDS; 1995; 9 Suppl A():S117-36. PubMed ID: 8819579
[No Abstract] [Full Text] [Related]
11. Hypervariable epitope constructs representing variability in envelope glycoprotein of SIV induce a broad humoral immune response in rabbits and rhesus macaques.
Meyer D; Anderson DE; Gardner MB; Torres JV
AIDS Res Hum Retroviruses; 1998 Jun; 14(9):751-60. PubMed ID: 9643375
[TBL] [Abstract][Full Text] [Related]
12. A clinically relevant HIV-1 subunit vaccine protects rhesus macaques from in vivo passaged simian-human immunodeficiency virus infection.
Mooij P; van der Kolk M; Bogers WM; ten Haaft PJ; Van Der Meide P; Almond N; Stott J; Deschamps M; Labbe D; Momin P; Voss G; Von Hoegen P; Bruck C; Heeney JL
AIDS; 1998 Mar; 12(5):F15-22. PubMed ID: 9543435
[TBL] [Abstract][Full Text] [Related]
13. Targeted lymph-node immunization with whole inactivated simian immunodeficiency virus (SIV) or envelope and core subunit antigen vaccines does not reliably protect rhesus macaques from vaginal challenge with SIVmac251.
Lü X; Kiyono H; Lu D; Kawabata S; Torten J; Srinivasan S; Dailey PJ; McGhee JR; Lehner T; Miller CJ
AIDS; 1998 Jan; 12(1):1-10. PubMed ID: 9456249
[TBL] [Abstract][Full Text] [Related]
14. Vaccination of rhesus macaques with recombinant Mycobacterium bovis bacillus Calmette-Guérin Env V3 elicits neutralizing antibody-mediated protection against simian-human immunodeficiency virus with a homologous but not a heterologous V3 motif.
Someya K; Cecilia D; Ami Y; Nakasone T; Matsuo K; Burda S; Yamamoto H; Yoshino N; Kaizu M; Ando S; Okuda K; Zolla-Pazner S; Yamazaki S; Yamamoto N; Honda M
J Virol; 2005 Feb; 79(3):1452-62. PubMed ID: 15650171
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of a candidate human immunodeficiency virus type 1 (HIV-1) vaccine in macaques: effect of vaccination with HIV-1 gp120 on subsequent challenge with heterologous simian immunodeficiency virus-HIV-1 chimeric virus.
Stott EJ; Almond N; Kent K; Walker B; Hull R; Rose J; Silvera P; Sangster R; Corcoran T; Lines J; Silvera K; Luciw P; Murphy-Corb M; Momin P; Bruck C
J Gen Virol; 1998 Mar; 79 ( Pt 3)():423-32. PubMed ID: 9519819
[TBL] [Abstract][Full Text] [Related]
16. Humoral immunity to HIV, SIV, and SHIV.
Haigwood NL; Zolla-Pazner S
AIDS; 1998; 12 Suppl A():S121-32. PubMed ID: 9632993
[No Abstract] [Full Text] [Related]
17. Immunization with virion-derived glycoprotein 130 from HIV-2 or SIV protects macaques against challenge virus grown in human or simian cells or prepared ex vivo.
Stahl-Hennig C; Coulibaly C; Petry H; Voss G; Dittmer U; Bodemer W; Makoschey B; Jurkiewicz E; Lüke W; Hunsmann G
AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S27-32. PubMed ID: 7865316
[TBL] [Abstract][Full Text] [Related]
18. In vivo induction of cellular and humoral immune responses by hybrid DNA vectors encoding simian/human immunodeficiency virus/hepatitis B surface antigen virus particles in BALB/c and HLA-A2-transgenic mice.
Marsac D; Puaux AL; Rivière Y; Michel ML
Immunobiology; 2005; 210(5):305-19. PubMed ID: 16164038
[TBL] [Abstract][Full Text] [Related]
19. GP120: target for neutralizing HIV-1 antibodies.
Pantophlet R; Burton DR
Annu Rev Immunol; 2006; 24():739-69. PubMed ID: 16551265
[TBL] [Abstract][Full Text] [Related]
20. Progress with HIV vaccines.
Biberfeld G; Emini EA
AIDS; 1991; 5 Suppl 2():S129-33. PubMed ID: 1845044
[No Abstract] [Full Text] [Related]
[Next] [New Search]
